M. Scott Salka

M. Scott Salka is Chief Executive Officer of AmpliPhi Biosciences Corporation. Mr. Salka joined the company in May 2015. Prior to AmpliPhi, Mr. Salka served as CEO of Aspyrian Therapeutics Inc., a company focused on developing near-infrared photoimmunotherapy — PIT — therapies. Mr. Salka was the CEO of Ambit Biosciences — acquired by Daiichi Sankyo — in 2014. During Mr. Salka’s tenure at Ambit, a company developing treatments for oncology, autoimmune and inflammatory diseases, he was responsible for transforming the company from a service contract business to a fully capable drug discovery and development enterprise. Prior to joining Ambit in 2001, he served as the President and Chief Executive Officer of two privately held genomics companies: Arcaris, Inc., and 454 Corporation — sold to Roche in 2007. He also previously co-founded one of the first commercial genomics companies, Sequana Therapeutics, Inc., a pioneer in the effort to commercialize the international Human Genome Project. Mr. Salka has also been a board member of Sorrento Therapeutics, Inc., and San Diego State University College of Business Administration. He received his MBA from Carnegie Mellon University and his B.S. in finance from San Diego State University.